Dr. Reddy: Generic potential - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy: Generic potential

Jun 4, 2001

The recent decision of a US court of appeals in favour of Barr Labs for launch of fluoxetine 10 mg / 20 mg (generic Prozac, an blockbuster anti-depressant drug) has come as a blessing in disguise for Dr. Reddy’s. The decision thus invalidates the patent protection to Eli Lilly, the original patent holder, that would have prevented any generic competition for the drug prior to December 2003. While Barr case was for 10 mg / 20 mg exclusivity, Dr. Reddy’s has a similar case (for the same drug) for 40 mg dosage. With the decision for 10 mg / 20 mg dosage now in favour of the Barr, one can expect a similar decision for 180 days generic exclusivity in favour of Dr. Reddy’s. The potential for Dr. Reddy’s is huge given that the annual branded sales for fluoxetine are in the range of US $ 275 m . Further, the court case for marketing generic version of prilosec (generic Omeprazole) has also inched in favour of Dr. Reddy’s. Prilosec, (another blockbuster product for gastro-intestinal disorders) has estimated sales of more than US$ 4 bn. Dr. Reddy's is expecting to get ‘first to file’ status and consequently, 180 days exclusivity for 40 mg version of omeprazole, and also plans to market other versions once the exclusivity period for those versions is over.

Both the developments further strengthens Dr. Reddy’s thrust to expand into high margin US generics market. It may be recalled that the company notched up maiden sales of US$ 6.5 m during its first four months of operations (December to march 2001), successfully gaining strong market share in recent launches (Famotidine and Oxaprozin). The company has forged alliances with top-tier companies (Par, Leiner Healthcare, Warrick) to ensure timely launches for its pipeline products through co-marketing and rapidly acquiring a critical mass in the US generic market.

Dr. Reddy currently has 28 Abbreviated New Drug Application (ANDA) filings to its credit. The company plans to file 11 new ANDAs in the US in the current year. Together, all ANDA filings of the company should sustain a strong revenue momentum from the generics markets in the next 2-3 years. It is expected that the company can notch up revenues of close to US$ 45 m from its US generic operations, if it is able to bag the 180 days marketing exclusivity for fluoxetine.


Equitymaster requests your view! Post a comment on "Dr. Reddy: Generic potential ". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 18, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS